The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).
It is very uncertain whether comparison 3: anticonvulsant levetiracetam changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 4: antipsychotics changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 5: benzodiazepines changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 1: 5HT1A partial agonists changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 8: NARIs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 9: NaSSAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
It is very uncertain whether comparison 10: RIMAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 12: SNRIs probably leads to higher dropouts due to adverse events (acute phase) compared with placebo (moderate certainty).
It is very uncertain whether comparison 2: anticonvulsants/GABAs changes dropouts due to adverse events (acute phase) compared with placebo (very low certainty).
Comparison 13: SSRIs may leads to higher dropouts due to adverse events (acute phase) compared with placebo (low certainty).
Comparison 14: GW876008 showed no clear difference in dropouts due to adverse events (acute phase) compared with placebo (low certainty).
Complete cure and adverse events for terbinafine showed no clear difference in adverse events attributed to the study drugs compared with griseofulvin (moderate certainty).
The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).